AirXpanders (ASX:AXP), a medical device company focused on the design, manufacture, sale and distribution of the AeroForm Tissue Expander System, has announced its manufacturing transfer to a contract manufacturer in Costa Rica is complete and manufacturing capability for its AeroForm device is operational.
The company said additional production capacity will enable the company to cost-effectively manufacture a higher volume of AeroForm expanders to meet growing market demand for the product, which is now available in more than 100 US hospitals. The new production line has a capacity to produce up to 20,000 units per year.
The manufacturing plant in Costa Rica is owned and operated by MedPlast, a leading global expert in medical device development, manufacturing, and assembly, with more than 35 years of experience partnering with leading global medical device companies.
AirXpanders will maintain its existing manufacturing facility in California with capacity of up to 4,000 units per year.
“Creating access to AeroForm for every eligible patient is mission critical for us, and our new manufacturing capacity supports our ability to make that happen,” said Scott Dodson, president and CEO. “We are delighted to have delivered on our commitment to open the Costa Rica manufacturing facility, enabling us to meet the growing demand for AeroForm and pave the way for improvements in gross margins. The scale of the MedPlast facility gives us the ability to readily add additional manufacturing lines for added capacity as we broaden our sales and marketing activities across the United States and around the world.”